BACKGROUND: The malignancy-risk gene signature is composed of numerous proliferative genes and has been applied to predict breast cancer risk. We hypothesized that the malignancy-risk gene signature has prognostic and predictive value for early-stage non-small cell lung cancer (NSCLC) patients. METHODS: The ability of the malignancy-risk gene signature to predict overall survival (OS) of early-stage NSCLC patients was tested using a large NSCLC microarray dataset from the Director's Challenge Consortium (n = 442) and two independent NSCLC microarray datasets (n = 117 and 133, for the GSE13213 and GSE14814 datasets, respectively). An overall malignancy-risk score was generated by principal component analysis to determine the prognostic and predictive value of the signature. An interaction model was used to investigate a statistically significant interaction between adjuvant chemotherapy (ACT) and the gene signature. All statistical tests were two-sided. RESULTS: The malignancy-risk gene signature was statistically significantly associated with OS (P < .001) of NSCLC patients. Validation with the two independent datasets demonstrated that the malignancy-risk score had prognostic and predictive values: Of patients who did not receive ACT, those with a low malignancy-risk score had increased OS compared with a high malignancy-risk score (P = .007 and .01 for the GSE13212 and GSE14814 datasets, respectively), indicating a prognostic value; and in the GSE14814 dataset, patients receiving ACT survived longer in the high malignancy-risk score group (P = .03), and a statistically significant interaction between ACT and the signature was observed (P = .02). CONCLUSIONS: The malignancy-risk gene signature was associated with OS and was a prognostic and predictive indicator. The malignancy-risk gene signature could be useful to improve prediction of OS and to identify those NSCLC patients who will benefit from ACT.
BACKGROUND: The malignancy-risk gene signature is composed of numerous proliferative genes and has been applied to predict breast cancer risk. We hypothesized that the malignancy-risk gene signature has prognostic and predictive value for early-stage non-small cell lung cancer (NSCLC) patients. METHODS: The ability of the malignancy-risk gene signature to predict overall survival (OS) of early-stage NSCLCpatients was tested using a large NSCLC microarray dataset from the Director's Challenge Consortium (n = 442) and two independent NSCLC microarray datasets (n = 117 and 133, for the GSE13213 and GSE14814 datasets, respectively). An overall malignancy-risk score was generated by principal component analysis to determine the prognostic and predictive value of the signature. An interaction model was used to investigate a statistically significant interaction between adjuvant chemotherapy (ACT) and the gene signature. All statistical tests were two-sided. RESULTS: The malignancy-risk gene signature was statistically significantly associated with OS (P < .001) of NSCLCpatients. Validation with the two independent datasets demonstrated that the malignancy-risk score had prognostic and predictive values: Of patients who did not receive ACT, those with a low malignancy-risk score had increased OS compared with a high malignancy-risk score (P = .007 and .01 for the GSE13212 and GSE14814 datasets, respectively), indicating a prognostic value; and in the GSE14814 dataset, patients receiving ACT survived longer in the high malignancy-risk score group (P = .03), and a statistically significant interaction between ACT and the signature was observed (P = .02). CONCLUSIONS: The malignancy-risk gene signature was associated with OS and was a prognostic and predictive indicator. The malignancy-risk gene signature could be useful to improve prediction of OS and to identify those NSCLCpatients who will benefit from ACT.
Authors: Jean-Yves Douillard; Rafael Rosell; Mario De Lena; Francesco Carpagnano; Rodryg Ramlau; Jose Luis Gonzáles-Larriba; Tomasz Grodzki; Jose Rodrigues Pereira; Alain Le Groumellec; Vito Lorusso; Claude Clary; Antonio J Torres; Jabrail Dahabreh; Pierre-Jean Souquet; Julio Astudillo; Pierre Fournel; Angel Artal-Cortes; Jacek Jassem; Leona Koubkova; Patricia His; Marcello Riggi; Patrick Hurteloup Journal: Lancet Oncol Date: 2006-09 Impact factor: 41.316
Authors: Marcin Skrzypski; Ewa Jassem; Miquel Taron; Jose Javier Sanchez; Pedro Mendez; Witold Rzyman; Grazyna Gulida; Dan Raz; David Jablons; Mariano Provencio; Bartomeu Massuti; Imane Chaib; Laia Perez-Roca; Jacek Jassem; Rafael Rosell Journal: Clin Cancer Res Date: 2008-08-01 Impact factor: 12.531
Authors: Katherine M W Pisters; William K Evans; Christopher G Azzoli; Mark G Kris; Christopher A Smith; Christopher E Desch; Mark R Somerfield; Melissa C Brouwers; Gail Darling; Peter M Ellis; Laurie E Gaspar; Harvey I Pass; David R Spigel; John R Strawn; Yee C Ung; Frances A Shepherd Journal: J Clin Oncol Date: 2007-10-22 Impact factor: 44.544
Authors: Jean-Pierre Pignon; Hélène Tribodet; Giorgio V Scagliotti; Jean-Yves Douillard; Frances A Shepherd; Richard J Stephens; Ariane Dunant; Valter Torri; Rafael Rosell; Lesley Seymour; Stephen G Spiro; Estelle Rolland; Roldano Fossati; Delphine Aubert; Keyue Ding; David Waller; Thierry Le Chevalier Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Jill E Larsen; Sandra J Pavey; Linda H Passmore; Rayleen V Bowman; Nicholas K Hayward; Kwun M Fong Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: Jennifer Permuth-Wey; Dung-Tsa Chen; William J Fulp; Sean J Yoder; Yonghong Zhang; Christina Georgeades; Kazim Husain; Barbara Ann Centeno; Anthony M Magliocco; Domenico Coppola; Mokenge Malafa Journal: Cancer Prev Res (Phila) Date: 2015-09
Authors: Lu Chen; Brienne E Engel; Eric A Welsh; Sean J Yoder; Stephen G Brantley; Dung-Tsa Chen; Amer A Beg; Chunxia Cao; Frederic J Kaye; Eric B Haura; Matthew B Schabath; W Douglas Cress Journal: J Thorac Oncol Date: 2016-02-23 Impact factor: 15.609
Authors: David D Stenehjem; Brandon K Bellows; Kraig M Yager; Joshua Jones; Rajesh Kaldate; Uwe Siebert; Diana I Brixner Journal: Oncologist Date: 2015-11-27
Authors: Hao Tang; Guanghua Xiao; Carmen Behrens; Joan Schiller; Jeffrey Allen; Chi-Wan Chow; Milind Suraokar; Alejandro Corvalan; Jianhua Mao; Michael A White; Ignacio I Wistuba; John D Minna; Yang Xie Journal: Clin Cancer Res Date: 2013-01-28 Impact factor: 12.531